Innovent Announces Sintilimab in Combination with Chemotherapy Meets the Primary Endpoint of Overall Survival in the Phase 3 ORIENT-16 Study for the First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Source :: PR Newswire. August 15, 2021
Publication Year :: 2021
Abstract: SAN FRANCISCO and SUZHOU, China, Aug. 15, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the [...]

Subjects :: Adenocarcinoma -- Care and treatment -- Patient outcomes -- Research
Metastasis -- Care and treatment -- Research -- Patient outcomes
Pemetrexed -- Product development -- Research
Clinical trials -- Research
Adalimumab -- Research -- Product development
Chemotherapy -- Research
Cancer -- Chemotherapy
Business
News, opinion and commentary

Tools